(Q38471032)

3 September 2017

title

Changes in the continuation of antihypertensive drug use after ALLHAT. (English)

1 reference

3 September 2017

Fagen Xie

1

1 reference

3 September 2017

Diana B Petitti

series ordinal

2

1 reference

3 September 2017

Joel Handler

series ordinal

3

1 reference

3 September 2017

publication date

1 November 2005

1 reference

Journal of Clinical Hypertension

3 September 2017

published in

1 reference

3 September 2017

volume

7

1 reference

3 September 2017

issue

11

1 reference

3 September 2017

page(s)

649-653

1 reference

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04788.X

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04788.X

Continuation of initial antihypertensive medication after 1 year of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04788.X

Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04788.X

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04788.X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04788.X

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04788.X

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04788.X

Changes in Prescribing Patterns Following Publication of the ALLHAT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.04788.X

10.1111/J.1524-6175.2005.04788.X

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference